Epaminurad
Epaminurad is an investigational new drug being developed by JW Pharmaceutical for the treatment of gout and hyperuricemia.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Epaminurad is an investigational new drug being developed by JW Pharmaceutical for the treatment of gout and hyperuricemia. It is a urate-lowering agent that selectively inhibits the human uric acid transporter 1 (hURAT1), promoting urate excretion. As of 2024, epaminurad is undergoing Phase 3 clinical trials to evaluate its efficacy and safety compared to febuxostat in gout patients across multiple Asian countries.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1330275818 under CC BY-SA 4.0; modifications have been made.